Revance Therapeutics (NASDAQ:RVNC) Stock Rating Lowered by Piper Sandler

Revance Therapeutics (NASDAQ:RVNC – Get Free Report) was downgraded by equities researchers at Piper Sandler from a “strong-buy” rating to a “hold” rating in a note issued to investors on Monday, Zacks.com reports. A number of other research analysts also recently issued reports on the company. Stifel Nicolaus cut their price target on Revance Therapeutics […]

Leave a Reply

Your email address will not be published.

Previous post AnaptysBio (NASDAQ:ANAB) Given New $30.00 Price Target at Truist Financial
Next post abrdn plc (OTCMKTS:SLFPY) Announces $0.32 Dividend